Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 2,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Comparison Arm Clear all

Conditions: Metabolic Syndrome, Protection Against, Diet, Healthy
Interventions: Home-Based Video and Motivational Interviewing Intervention, Read Educate and Develop Youth (READY) Comparison; Behavioral
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 257 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Anatomic Total Shoulder Arthroplasty
Interventions: DePuy Global® Anchor Peg Glenoid Instrumentation, DePuy Global® Anchor Peg Instrumentation with SmartBone™, IRI with SmartBone™, RTI with SmartBone™, IRI with SmartBase; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Actinic Porokeratosis
Interventions: Lovastatin 2%, 2% Cholesterol Cream, Lovastatin 2% Cream; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
Interventions: rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®), Flotufolastat F18; Radiation · Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Relapsed or Refractory Follicular Lymphoma
Interventions: Mosunetuzumab, Lenalidomide, Rituximab, Tociluzumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 17
States / cities: Duarte, California • Atlanta, Georgia • Fort Wayne, Indiana + 13 more

Conditions: Infections, Wounds and Injuries
Interventions: Silverlon®, AQUACEL® AG; Device
Lead sponsor: Kansas City Heart Rhythm Institute; Other
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Covid19
Interventions: Acebilustat, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Diet, Healthy
Interventions: Customized meal plan and grocery delivery; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Sexually Transmitted Disease (STD), Gonorrhea, Chlamydia, Trichomonas Infection
Interventions: Self-swab collection PCR test for chlamydia, gonorrhea, trichomonas; Diagnostic Test
Lead sponsor: Queen's Medical Center; Other
Eligibility: 14 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin Degludec, Insulin Glargine, TRESIBA® FLEXTOUCH®, LANTUS® SOLOSTAR® INSULIN PEN; Drug · Device
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Santa Barbara, California • Honolulu, Hawaii

Conditions: Cataract
Interventions: Dexamethasone Phosphate Ophthalmic, 100 mM Sodium Citrate Buffer; Drug
Lead sponsor: Eyegate Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 3
States / cities: Miami, Florida • Tamarac, Florida • Washington, Missouri

Conditions: Kidney Stone
Interventions: SOLTIVE Thulium Fiber Laser, Ho:YAG Laser; Device
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Post-Traumatic Stress Disorder
Interventions: BNC210, Placebo; Drug
Lead sponsor: Bionomics Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 25
States / cities: Bellflower, California • Beverly Hills, California • Colton, California + 22 more

Conditions: Chronic Kidney Disease and Hypertension
Interventions: Baxdrostat/dapagliflozin, Placebo/dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 133
States / cities: Fairhope, Alabama • Surprise, Arizona • Tucson, Arizona + 117 more

Conditions: Multiple Sclerosis
Interventions: Rebif; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone, Enzalutamide, Apalutamide, Darolutamide, Deutenzalutamide, Radium-223; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 28
States / cities: Dothan, Alabama • Phoenix, Arizona • Duarte, California + 24 more

Conditions: Esophageal Squamous Cell Carcinoma
Interventions: LJM716, BYL719, Paclitaxel, Docetaxel, Irinotecan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Chicago, Illinois • Detroit, Michigan • Houston, Texas

Conditions: Social Anxiety Disorder
Interventions: Group CBT for Social Anxiety Disorder, Sertraline, Individual CBT for Social Anxiety Disorder; Behavioral · Drug
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years to 50 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Failure
Interventions: Eplerenone; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 2,743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 51
States / cities: Phoenix, Arizona • Loma Linda, California • Merced, California + 37 more

Conditions: Spinal Cord Injuries
Interventions: Neurophysiological and anatomical testing, Transcutaneous Spinal Stimulation; Diagnostic Test · Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Sacramento, California

Conditions: HIV Infections
Interventions: Interleukin-2 SA, HAART; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 9
States / cities: Birmingham, Alabama • Davis, California • Los Angeles, California + 5 more

Conditions: Wounds
Interventions: Placebo gel, GLYC-101 gel (1.0 %); Drug
Lead sponsor: TR Therapeutics; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Healthy
Interventions: Isosorbide dinitrate / hydralazine capsules; Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Hackensack, New Jersey

Search by objective public record fields.

Strong Families Start at Home/Familias Fuertes Comienzan en Casa

Evaluation of the Bioequivalence of a Combined Formulated Tablet

Comparison of Glenoid Position Using SmartBones

DSAP Treatment Comparison: 2% Lovastatin/ 2% Cholesterol vs 2% Lovastatin Alone

Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

Comparison of Outcomes Between the Use of Silverlon® Dressing and AQUACEL® AG Dressing Post Cardiac Device Implant

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol

FOOD PRESCRIPTION APP

Assessing Acceptability and Feasibiity of STI Self-swab Testing, to be Offered at the Time of Telemed Medication Abortion Provision

Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.

Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOL

Clinical Outcomes and Healthcare Economics of SOLTIVE Compared to Ho:YAG Laser in Urolithiasis

A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)

Neural Markers of Treatment Mechanisms and Prediction of Treatment Outcomes in Social Anxiety

A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines

Spinal Neurorehabilitation for Veterans With SCI

Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection

Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation

A Comparison of Various Combinations of BiDil Capsules and BiDil Tablets in Healthy Human Volunteers